Scopus BioPharma (NASDAQ:SCPS) Shares Down 8.3%
Scopus BioPharma (NASDAQ:SCPS) Shares Down 8.3%
Shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) dropped 8.3% on Wednesday . The company traded as low as $0.10 and last traded at $0.11. Approximately 21,957 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 55,127 shares. The stock had previously closed at $0.12.
斯科普斯生物製藥股份有限公司（NASDAQ：SCP-獲得評級）週三下降了 8.3％。該公司的交易價格低至 0.10 美元，最後交易價格為 0.11 美元。在中間交易期間，約 21,957 股股份成交手，較每日 55,127 股的平均成交量下降 60%。該股票之前已收盤 0.12 美元。
Scopus BioPharma Stock Down 8.3 %
科普斯生物製藥股票下跌 8.3%
The business's fifty day moving average price is $0.17 and its two-hundred day moving average price is $0.28.
該企業的五十天移動平均價格為 0.17 美元，其 200 天移動平均價格為 0.28 美元。
Institutional Investors Weigh In On Scopus BioPharma
機構投資者權衡 Scopus 生物製藥
An institutional investor recently raised its position in Scopus BioPharma stock. Renaissance Technologies LLC grew its stake in shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 112,523 shares of the company's stock after acquiring an additional 91,623 shares during the period. Renaissance Technologies LLC owned about 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.16% of the company's stock.
一名機構投資者最近提高了其在 Scopus 生物製藥股票的地位。根據其最近與美國證券交易委員會的披露資料，文藝復興科技有限責任公司在第一季度增加了 438.4％，其在 Scopus 生物製藥公司（NASDAQ：SCP-獲得評級）的股份的股份增長了 438.4％。在期內，機構投資者在該期間額外購入 91,623 股股份後擁有該公司股票的 112,523 股。在最近一個季度末，文藝復興科技有限公司擁有約 0.53％ 的 Scopus 生物製藥，價值 78,000 美元。對沖基金和其他機構投資者擁有公司股票的 2.16%。
Scopus BioPharma Company Profile
科邦生物製藥公司簡介
Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Scopus 生物製藥公司是臨床階段的生物製藥公司，致力於開發針對嚴重疾病的轉型治療。該公司的領導開發計劃是用於治療各種癌症的免疫腫瘤基因療法。它提供 Duet 平台，CpG 信號傳感器和轉錄 3（STAT3）抑製劑的激活劑; 和 MRI-1867，合理設計，口服，雙作用，混合和小分子，是內源性大麻素系統/大麻素受體 1 的反激動劑，以及誘發一氧化氮合成酶的抑製劑。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 免費索取有關 Scopus 生物製藥的研究報告
- 寶潔公司的收益：值得參加的賭博
- 股票幻燈片，經濟報告描繪經濟陰沉的圖片
- NU 控股股票與沃倫·巴菲特有什麼關係？
- J.B. 亨特得到一個單位, 物流公司成為焦點
- 英特爾股票是否瀕臨爆發？
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Scopus 生物製藥日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子報收到 Scopus 生物製藥和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。